AI주식인사이트AI Stock Insight
C

뷰노

338220KOSDAQ

53.5 / 100

Reference Date: 2026-10-23

Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure14.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 39.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

VUNO is a pioneer in medical IT, leveraging deep learning to provide innovative solutions such as cardiac arrest prediction, fundus image analysis, and chest X-ray diagnostics. Its key product, VUNO Med-DeepCARS, received FDA Breakthrough Device Designation in 2023 and is actively expanding into the U.S. market. The company is transitioning to a SaaS-based subscription model, with the prognosis and prediction solutions driving the majority of its revenue.

Number of Employees

165people

Average Salary

80.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
2.33Industry Average 1.201.0Point

1.9x industry avg (risky)

ROE
-17.30Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
5.13Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲64.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -74.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 6,020Won52-week high 27,60052-week low 4,325
1-month return6.0Point

1m +39.19% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 2Neutral 6Negative 0
  • Neutral임원ㆍ주요주주특정증권등거래계획철회보고서2026-10-22
  • Neutral[기재정정]증권신고서(지분증권)2026-10-15
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-10-15
  • Neutral임원ㆍ주요주주특정증권등거래계획철회보고서2026-10-06
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-10-06